Results 171 to 180 of about 4,769,368 (347)

Outcome bias and cognitive dissonance in evaluating treatment decisions

, 1994
Larry D. Gruppen, J Margolin, Kimberlydawn Wisdom, Cyril M. Grum   +3 more
openalex   +1 more source

Early metastasis is characterized by Gr1+ cell dysregulation and is inhibited by immunomodulatory nanoparticles

Molecular Oncology, EarlyView.
Breast cancer metastasis is associated with myeloid cell dysregulation and the lung‐specific accumulation of tumor‐supportive Gr1+ cells. Gr1+ cells support metastasis, in part, through a CHI3L1‐mediated mechanism, which can be targeted and inhibited with cargo‐free, polymeric nanoparticles.
Jeffrey A. Ma, Sophia M. Orbach, Kate V. Griffin, Kathryn Kang, Yining Zhang, Rebecca S. Pereles, Ian A. Schrack, Guillermo Escalona, Jacqueline S. Jeruss, Lonnie D. Shea   +9 more
wiley   +1 more source

Evaluating treatment outcomes [PDF]

Psychiatric Bulletin, 1990
Jacqueline Bailey, Phil Anthony, David Thompson   +2 more
openaire   +2 more sources

The 60 Minutes Myocardial Infarction Project: Treatment and clinical outcome of patients with acute myocardial infarction in Germany [PDF]

, 1997
Jörg Rüstige, Rudolf Schiele, Udo Burczyk, Armin Koch, Martin Gottwik, K. L. Neuhaus, Ulrich Tebbe, R. Uebis, Jochen Senges   +8 more
openalex   +1 more source

Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data

Molecular Oncology, EarlyView.
This study develops a semi‐supervised classifier integrating multi‐genomic data (1404 training/5893 validation samples) to improve homologous recombination deficiency (HRD) detection in breast cancer. Our method demonstrates prognostic value and predicts chemotherapy/PARP inhibitor sensitivity in HRD+ tumours.
Rong Zhu, Katherine Eason, Suet‐Feung Chin, Paul A. W. Edwards, Raquel Manzano Garcia, Richard Moulange, Jia Wern Pan, Soo Hwang Teo, Sach Mukherjee, Maurizio Callari, Carlos Caldas, Stephen‐John Sammut, Oscar M. Rueda   +12 more
wiley   +1 more source

Clinical characteristics and treatment outcome in p16 negative anal cancer. [PDF]

Acta Oncol
Burgos C, Radu C, Heyman S, Cavalli-Björkman N, Nygren P.   +4 more
europepmc   +1 more source

Induction of the Antigen 85 Complex ofMycobacterium tuberculosisin Sputum: A Determinant of Outcome in Pulmonary Tuberculosis Treatment [PDF]

, 1998
Robert S. Wallis, Mark D. Perkins, Manijeh Phillips, Moses Joloba, Barbara S. Demchuk, Alice Namale, John L. Johnson, Donna M. Williams, Kathy Wolski, Luciléia Teixeira, Reynaldo Dietze, Roy D. Mugerwa, Kathleen D. Eisenach, Jerrold J. Ellner   +13 more
openalex   +1 more source

Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8‐year study of 10 754 patients in Turkey

Molecular Oncology, EarlyView.
This nationwide study evaluated KRAS and NRAS mutations in 10 754 Turkish patients with metastatic colorectal cancer. The results revealed a mutation frequency of 51.1%, with 46.6% having KRAS mutations, 4.5% having NRAS mutations, and 48.5% being wild‐type for both.
Gozde Kavgaci, Izzet Akiva, Yavuz Hakan Ozon, Hakan Berkil, Huseyin Karadayi, Omer Dizdar, Suayib Yalcin   +6 more
wiley   +1 more source

Multi-level treatment outcome evaluation in adolescents with autism spectrum disorder. [PDF]

Child Adolesc Psychiatry Ment Health
Auer GA, Plener PL, Poustka L, Konicar L.   +3 more
europepmc   +1 more source

Social Support Resource Outcomes for the Clients of Two Assertive Community Treatment Teams

, 1994
Joseph Walsh
openalex   +2 more sources